Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud. You can reach Allison on Signal at AllisonDeAngelis.01.

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70.

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54.

Was Hims’ Super Bowl ad the final straw for regulators? Is the bar being lowered for psychedelic medicines? And what’s happening behind-the-scenes with Moderna and the Food and Drug Administration?

We discuss all that on this week’s episode of “The Readout LOUD.” STAT’s Katie Palmer joins Adam, Elaine, and Allison to discuss the Hims GLP-1 pill fallout. The hosts also discuss the latest on Moderna’s influenza vaccine application and Compass Pathways’ depression psychedelic data.

Advertisement

To read more about the potential crackdown on compounding, go here. To read more about Hims’ blood testing push, go here. For details on Hims’ acquisition of telehealth company Eucalyptus, click here. For details on the FDA’s new guidance for Moderna, click here. And to read about Compass’ clinical trial results, go here.

Be sure to sign up for “The Readout LOUD” on Apple PodcastsSpotify, or wherever you get your podcasts.